Atul Pande is a drug and device development expert with 25 years of industry experience.

He currently serves as Chief Medical Officer of Boston-based PureTech Health. He is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline.

Dr. Pande has been active in the development of multiple investigational and now marketed drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories.

Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. He currently serves; on the Board of Directors of PureTech Health’s Karuna Pharmaceuticals. He also sits on the Board of Axovant Sciences (NASDAQ:AXON) and on the Scientific Advisory Boards of Datavant, Centrexion Corporation and Cennerv Pharma.

Dr. Pande began his career as a professor at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.